Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/Ho95 MM trial)

被引：44

作者：

Cavo, Michele

Palumbo, Antonio

Zweegman, Sonja

Dimopoulos, Meletios A.

Hajek, Roman

Pantani, Lucia

Beksac, Meral

Wester, Ruth

Johnsen, Hans E.

Mellqvist, Ulf -Henrik

Petrucci, Maria Teresa

Driessen, Christoph

Di Raimondo, Francesco

Troia, Rossella

Pezzi, Annalisa

Van der Holt, Bronno

Wu, Ka Lung

Ludwig, Heinz

Gay, Francesca

Sonneveld, Pieter

机构：

[1] Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

[2] Univ Torino, Div Hematol, Myeloma Unit, Azienda Osped Citta Salute & Sci Torino, Turin, Italy

[3] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[4] Univ Athens, Sch Med, Athens, Greece

[5] Masaryk Univ Hosp, Brno, Czech Republic

[6] Ankara Univ, Tip Fak, Ankara, Turkey

[7] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

[8] Aalborg Univ Hosp, Dept Hematol, Clin Canc Res Ctr, Aalborg, Denmark

[9] South Elvsborg Hosp, Boras, Sweden

[10] Sapienza Univ Rome, Dept Hematol, Rome, Italy

[11] Kantonsspital St Gallen, St Gallen, Switzerland

[12] Univ Catania, Div Hematol, Osped Ferrarotto, Catania, Italy

[13] Erasmus MC Canc Inst, Clin Trial Ctr, HOVON Data Ctr, Rotterdam, Netherlands

[14] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[15] Wilhelminen Canc Res Inst, Dept Med, Ctr Oncol Hematol & Palliat Care, Wilhelminenspital, Vienna, Austria

[16] Erasmus MC, Rotterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.8000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8000

引用

页数：2